

Rating Hold

North America United States

Health Care

Contract Research Organizations

Quintiles Transnational

Reuters Bloomberg Q.N Q US Exchange Ticker NYS Q

Date 2 May 2014

Forecast Change

Price at 1 May 2014	48.76
Price target	54.00
52-week range	54.94 - 0.00

George Hill

Research Analyst (+1) 212 250-2177 george.hill@db.com

Stephen Hagan, CFA

Research Associate (+1) 212 250-6875 stephen.hagan@db.coi

Key changes

Price target	53.00 to 54.00	1	1.9%
EPS (USD)	2.43 to 2.55	1	5.1%
Revenue (USDm)	-	1	0.0%

Source: Deutsche Bank

Price/price relative

56



Series1

Performance (%)	1m	3m	12m
Absolute	-4.6	2.4	613.9
S&P 500 INDEX	-0.1	5.7	19.0
Source: Deutsche Bank			

Quintiles Keeps Delivering; Valuation Keeps Us Neutral

Operating Leverage Outperforms

Quintiles reported 1Q14 results that exceeded our expectations as revenue slightly exceeded our forecast but operating leverage was strong than we forecast. EBITDA growth of 21% y/y was significantly ahead of the 8.4% revenue growth and our forecast for 14.6% EBITDA growth. Excluding a 4c benefit from non-operating items EPS was \$0.64, compared to our forecast for \$0.56 and consensus at \$0.55. Quintiles also reported solid book-to-bill of 1.27x. We maintain our Hold rating on Q shares on valuation but increase our price target to \$54 to reflect better operating margins in our 2015 forecast.

Broader Book of Business

Quintiles continues to deliver steady growth in revenue and bookings, with a solid improvement in IHS revenue in Q1. Quintiles benefits from having less customer concentration than other CROs and the IHS business provides the opportunity to cross sell other solutions to the customer base. Book-to-bill in the PDEV business of 1.30x was the best performance in four quarters and IHS at 1.15x was the third straight quarter of book-to-bill over 1.0x.

Revised Estimates

We have revised our estimates to reflect the better than expected operating leverage. Our 2014 and 2015 revenue estimates are largely unchanged, but our EPS estimates are increased. Our revised 2014 EPS estimate is \$2.55 and our revised 2015 EPS estimate is \$2.83. Quintiles could outperform our forecasts if bookings continue to exceed our projections or operating leverage continues to outperform.

Maintain Hold

We maintain our Hold rating on Quintiles and increase our price target to \$54. Our price target of \$54 is 19x our 2015 EPS estimate of \$2.83. We continue to have a negative view on CRO valuations but assign Quintiles a multiple in-line with the peer group median for 2014E, as Quintiles continues to deliver better organic revenue and bookings growth than competitors. Positive risks include faster than expected IHS growth, stronger CRO pricing, and new client wins. Negative risks are weaker IHS growth, slower outsourcing from PDEV clients, and client losses or contract revisions.

Forecasts And Ratios			
Year End Dec 31	2013A	2014E	2015E
1Q EPS	0.48	0.68A	_
2Q EPS	0.50	0.60	_
3Q EPS	0.54	0.62	_
4Q EPS	0.58	0.65	_
FY EPS (USD)	2.09	2.55	2.83
OLD FY EPS (USD)	2.09	2.43	2.79
% Change	0.0%	5.1%	1.3%
P/E (x)	20.9	19.1	17.2
Revenue (USDm)	3,808.3	4,148.8	4,490.8
Source: Deutsche Bank estimates, company data			

Deutsche Bank Securities Inc.

Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. DISCLOSURES AND ANALYST CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MCI (P) 148/04/2014.



Model updated:01 May 2014
Running the numbers
North America
United States
Contract Research Organizations

Quintiles Transnational

mberg: Q US
)

Hold Price (1 May 14) USD 48.76 Target Price USD 54.00 52 Week range USD 0.00 - 54.94


USDm 6,497 EURm 4,686

Company Profile


Market Cap (m)

Quintiles is a contract research organization (CRO) and the largest provider of biopharmaceutical development and commercial outsourcing services. The Company has 27,000 employees in approximately 100 countries and has helped develop or commercialize all of the top 50 best selling drugs on the market.


Price Performance




Margin Trends



Growth & Profitability



Solvency



George Hill +1 212 250-2177

1 212 250-2177 george.hill@db.com

Fiscal year end 31-Dec	2011	2012	2013	2014E	2015E	2016
Financial Summary						
DB EPS (USD)	1.62	1.77	2.09	2.55	2.83	3.0
Reported EPS (USD) DPS (USD)	2.05 0.00	1.51 0.00	1.77 0.00	2.50 0.00	2.84 0.00	3.0 0.0
BVPS (USD)	-8.23	-11.54	-5.22	-2.32	0.73	4.0
Valuation Metrics						
Price/Sales (x)	0.2	0.2	1.5	1.6	1.4	1
P/E (DB) (x)	4.3	3.9	20.9	19.1	17.2	16
P/E (Reported) (x) P/BV (x)	3.4 nm	4.6 nm	24.7 nm	19.5 nm	17.1 66.4	16 12
FCF yield (%)	10.4	32.2	5.5	6.3	7.8	8
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	(
EV/Sales	0.7	0.7	1.8	1.8	1.5	
EV/EBITDA	5.0	5.3	11.9	10.5	8.6	7
EV/EBIT	6.3	6.6	14.7	12.9	10.5	9
Income Statement (USDm)						
Sales	3,295	3,692	3,808	4,149	4,491	4,7
EBITDA	450	495	570	693	789	8
EBIT Pre-tax profit	358 185	396 267	462 323	565 470	645 544	6 5
Net income	242	178	227	334	380	4
Cash Flow (USDm)						
Cash flow from operations	161	336	397	512	609	6
Net Capex	-76	-71	-92	-100	-103	-1
Free cash flow	85	264	305	412	506	5
Equity raised/(bought back)	-13	-10	445	0	0	
Dividends paid	-288 249	-568 436	0 -386	0 -55	0 -22	
Net inc/(dec) in borrowings Other investing/financing cash flows	-163	-71	-153	-55	-22	_
Net cash flow	-130	51	210	357	484	5
Change in working capital	-83	12	60	23	57	
Balance Sheet (USDm)						
Cash and cash equivalents	516	568	778	1,135	1,619	2,1
Property, plant & equipment	186	194	200	215	224	2
Goodwill	278	302	410	410	410	4
Other assets Total assets	1,343 2,323	1,435 2,499	1,679 3,067	1,688 3,447	1,688 3,940	1,6 4,4
Debt	1,972	2,422	2,046	1,991	1,970	1,9
Other liabilities	1,321	1,436	1,688	1,765	1,873	1,9
Total liabilities	3,293	3,858	3,734	3,756	3,842	3,8
Total shareholders' equity	-970	-1,359	-667	-309	98	5
Net debt	1,456	1,854	1,268	856	350	-2
Key Company Metrics		40.4	0.4	0.0	0.0	
Sales growth (%) DB EPS growth (%)	nm na	12.1 9.5	3.1 18.0	8.9 22.0	8.2 10.8	!
Payout ratio (%)	0.0	0.0	0.0	0.0	0.0	
EBITDA Margin (%)	13.6	13.4	15.0	16.7	17.6	1
EBIT Margin (%)	10.9	10.7	12.1	13.6	14.4	1-
ROE (%)	nm	nm	nm	nm	nm	12
Net debt/equity (%)	nm 3.4	nm 3.0	nm	nm 5.7	356.9	-3
Net interest cover (x)	3.4	3.0	3.9	5.7	6.4	(
DuPont Analysis	10.0	10.7	10.1	10.0	14.4	1
EBIT margin (%) x Asset turnover (x)	10.9 1.4	10.7 1.5	12.1 1.4	13.6 1.3	14.4 1.2	1
x Financial cost ratio (x)	0.7	0.7	0.7	0.8	0.8	
x Tax and other effects (x)	1.0	0.7	0.7	0.7	0.7	
= ROA (post tax) (%)	10.4	7.4	8.1	10.2	10.3	,
x Financial leverage (x)	-2.4	-2.1	-2.7	-6.7	-35.0	1:
= ROE (%)	-24.9	-15.2	-22.4 46.7	-68.3	-360.8	129
annual growth (%) x NTA/share (avg) (x)	<i>na</i> -8.2	<i>38.8</i> -9.9	<i>-46.7</i> -7.9	<i>-205.6</i> -3.7	- <i>428.2</i> -0.8	:
= Reported EPS	2.05	1.51	1.77	2.50	2.84	3.

Page 2 Deutsche Bank Securities Inc.



Figure 1: Quintiles 1Q14 Results vs. DB Forecast

	<u>Q1-14</u>				Growth				
	<u>Estim</u>	ate		<u>Actual</u>	<u>Q1</u>	<u>-13A</u>	<u>Est</u>	<u>Act</u>	Comments
PDEV revenue		761.5		770.8		706.3	7.8%	9.1%	book to bill of 1.30x
IHS revenue		235.7		234.5		221.1	6.6%	6.0%	book to bill of 1.15x
Net sales		997.3		1,005.3		927.4	7.5%	8.4%	total book to bill of 1.27x
% change		7.5%		8.4%		0.0			
Cost of products sold		645.1		643.7		611.1	5.6%	5.3%	
% of revenue		64.7%		64.0%		0.7			
Gross profit		352.2		361.6		316.3	11.3%	14.3%	
Margin %		35.3%		36.0%		34.1%			
SG&A		221.3		219.2		199.3			
% of revenue		22.2%		21.8%		21.5%			
Adjusted income from operations		130.9		142.3		117.0	11.9%	21.6%	
EBIT Margin		13.1%		14.2%		12.6%			
Depreciation and amortization		31.4		29.1		24.6			
% of revenue		3.1%		2.9%		2.7%			
EBITDA		162.3		171.4		141.7	14.6%	21.0%	
EBITDA Margin		16.3%		17.1%		15.3%			
Income before income taxes and equity in earnings of affiliates		105.7		122.7		82.0			\$4.8mm benefit from other income
Taxes		31.7		37.4		32.1			
<u>Tax rate</u>		30.0%		30.5%		39.2%			
Income before equity in earnings of unconsolidated affiliates		74.0		85.3		49.8			
Equity in earnings of unconsolidated affiliate		0.5		4.9		(1.7)			\$4.9mm benefit from NovaQuest investment
Quintiles GAAP Net income		74.4		90.2		48.2			
Non-GAAP adjustments		0.1		0.7		9.0			
Quintiles non-GAAP Net Income		74.5		90.9		57.1	30.4%	59.2%	
GAAP EPS	\$	0.56		0.68	\$	0.41			
Non-GAAP EPS	\$	0.56	\$	0.68	\$	0.48	16.0%	42.1%	4c benefit from non-operating items
Weighted avg basic shares		129.4		129.9		115.8			
Weighted avg diluted shares		133.5		133.0		118.7			

Source: Deutsche Bank

Deutsche Bank Securities Inc. Page 3



Appendix 1

Important Disclosures

Additional information available upon request

Disclosure checklist			
Company	Ticker	Recent price*	Disclosure
Quintiles Transnational	Q.N	48.76 (USD) 1 May 14	1,7,14,15

^{*}Prices are sourced from local exchanges via Reuters, Bloomberg and other vendors. Data is sourced from Deutsche Bank and subject companies

Important Disclosures Required by U.S. Regulators

Disclosures marked with an asterisk may also be required by at least one jurisdiction in addition to the United States. See Important Disclosures Required by Non-US Regulators and Explanatory Notes.

- Within the past year, Deutsche Bank and/or its affiliate(s) has managed or co-managed a public or private offering for this company, for which it received fees.
- 7. Deutsche Bank and/or its affiliate(s) has received compensation from this company for the provision of investment banking or financial advisory services within the past year.
- 14. Deutsche Bank and/or its affiliate(s) has received non-investment banking related compensation from this company within the past year.
- 15. This company has been a client of Deutsche Bank Securities Inc. within the past year, during which time it received non-investment banking securities-related services.

Important Disclosures Required by Non-U.S. Regulators

Please also refer to disclosures in the Important Disclosures Required by US Regulators and the Explanatory Notes.

- Within the past year, Deutsche Bank and/or its affiliate(s) has managed or co-managed a public or private offering for this company, for which it received fees.
- 7. Deutsche Bank and/or its affiliate(s) has received compensation from this company for the provision of investment banking or financial advisory services within the past year.

For disclosures pertaining to recommendations or estimates made on securities other than the primary subject of this research, please see the most recently published company report or visit our global disclosure look-up page on our website at http://gm.db.com/ger/disclosure/Disclosure.eqsr?ricCode=Q.N


Analyst Certification

The views expressed in this report accurately reflect the personal views of the undersigned lead analyst(s) about the subject issuer and the securities of the issuer. In addition, the undersigned lead analyst(s) has not and will not receive any compensation for providing a specific recommendation or view in this report. George Hill

Page 4 Deutsche Bank Securities Inc.



Historical recommendations and target price: Quintiles Transnational (Q.N) (as of 5/1/2014)



Equity rating key

Buy: Based on a current 12- month view of total share-holder return (TSR = percentage change in share price from current price to projected target price plus pro-jected dividend yield), we recommend that investors buy the stock.

Sell: Based on a current 12-month view of total shareholder return, we recommend that investors sell the stock

Hold: We take a neutral view on the stock 12-months out and, based on this time horizon, do not recommend either a Buy or Sell.

Notes:


- 1. Newly issued research recommendations and target prices always supersede previously published research.
- 2. Ratings definitions prior to 27 January, 2007 were:

Buy: Expected total return (including dividends) of 10% or more over a 12-month period Hold: Expected total return (including

Hold: Expected total return (including dividends) between -10% and 10% over a 12-month period

Sell: Expected total return (including dividends) of -10% or worse over a 12-month period

Equity rating dispersion and banking relationships



-10% or worse over a 12-month period

Deutsche Bank Securities Inc.

2 May 2014 Contract Research Organizations Quintiles Transnational



Regulatory Disclosures

1. Important Additional Conflict Disclosures

Aside from within this report, important conflict disclosures can also be found at https://gm.db.com/equities under the "Disclosures Lookup" and "Legal" tabs. Investors are strongly encouraged to review this information before investing.

2. Short-Term Trade Ideas

Deutsche Bank equity research analysts sometimes have shorter-term trade ideas (known as SOLAR ideas) that are consistent or inconsistent with Deutsche Bank's existing longer term ratings. These trade ideas can be found at the SOLAR link at http://gm.db.com.

3. Country-Specific Disclosures

Australia and New Zealand: This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act and New Zealand Financial Advisors Act respectively.

Brazil: The views expressed above accurately reflect personal views of the authors about the subject company(ies) and its(their) securities, including in relation to Deutsche Bank. The compensation of the equity research analyst(s) is indirectly affected by revenues deriving from the business and financial transactions of Deutsche Bank. In cases where at least one Brazil based analyst (identified by a phone number starting with +55 country code) has taken part in the preparation of this research report, the Brazil based analyst whose name appears first assumes primary responsibility for its content from a Brazilian regulatory perspective and for its compliance with CVM Instruction # 483.

EU countries: Disclosures relating to our obligations under MiFiD can be found at http://www.globalmarkets.db.com/riskdisclosures.

Japan: Disclosures under the Financial Instruments and Exchange Law: Company name - Deutsche Securities Inc. Registration number - Registered as a financial instruments dealer by the Head of the Kanto Local Finance Bureau (Kinsho) No. 117. Member of associations: JSDA, Type II Financial Instruments Firms Association, The Financial Futures Association of Japan, Japan Investment Advisers Association. Commissions and risks involved in stock transactions - for stock transactions, we charge stock commissions and consumption tax by multiplying the transaction amount by the commission rate agreed with each customer. Stock transactions can lead to losses as a result of share price fluctuations and other factors. Transactions in foreign stocks can lead to additional losses stemming from foreign exchange fluctuations. "Moody's", "Standard & Poor's", and "Fitch" mentioned in this report are not registered credit rating agencies in Japan unless Japan or "Nippon" is specifically designated in the name of the entity. Reports on Japanese listed companies not written by analysts of Deutsche Securities Inc. (DSI) are written by Deutsche Bank Group's analysts with the coverage companies specified by DSI.

Qatar: Deutsche Bank AG in the Qatar Financial Centre (registered no. 00032) is regulated by the Qatar Financial Centre Regulatory Authority. Deutsche Bank AG - QFC Branch may only undertake the financial services activities that fall within the scope of its existing QFCRA license. Principal place of business in the QFC: Qatar Financial Centre, Tower, West Bay, Level 5, PO Box 14928, Doha, Qatar. This information has been distributed by Deutsche Bank AG. Related financial products or services are only available to Business Customers, as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This information, interpretation and opinions submitted herein are not in the context of, and do not constitute, any appraisal or evaluation activity requiring a license in the Russian Federation.

Kingdom of Saudi Arabia: Deutsche Securities Saudi Arabia LLC Company, (registered no. 07073-37) is regulated by the Capital Market Authority. Deutsche Securities Saudi Arabia may only undertake the financial services activities that fall within the scope of its existing CMA license. Principal place of business in Saudi Arabia: King Fahad Road, Al Olaya District, P.O. Box 301809, Faisaliah Tower - 17th Floor, 11372 Riyadh, Saudi Arabia.

United Arab Emirates: Deutsche Bank AG in the Dubai International Financial Centre (registered no. 00045) is regulated by the Dubai Financial Services Authority. Deutsche Bank AG - DIFC Branch may only undertake the financial services activities that fall within the scope of its existing DFSA license. Principal place of business in the DIFC: Dubai International Financial Centre, The Gate Village, Building 5, PO Box 504902, Dubai, U.A.E. This information has been distributed by Deutsche Bank AG. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority.

Page 6 Deutsche Bank Securities Inc.

49



David Folkerts-Landau

Group Chief Economist Member of the Group Executive Committee

Guy Ashton Global Chief Operating Officer Research

Marcel Cassard Global Head FICC Research & Global Macro Economics Richard Smith and Steve Pollard Co-Global Heads **Equity Research**

Michael Spencer Regional Head Asia Pacific Research

Ralf Hoffmann Regional Head Deutsche Bank Research, Germany

Andreas Neubauer Regional Head Equity Research, Germany

Steve Pollard Regional Head Americas Research

International locations

Deutsche Bank AG

Deutsche Bank Place Level 16 Corner of Hunter & Phillip Streets

Sydney, NSW 2000 Australia

Tel: (61) 2 8258 1234

Deutsche Bank AG

Große Gallusstraße 10-14 60272 Frankfurt am Main Germany

Tel: (49) 69 910 00

Deutsche Bank AG

Filiale Hongkong International Commerce Centre, 1 Austin Road West, Kowloon, Hong Kong

Tel: (852) 2203 8888

Deutsche Securities Inc.

2-11-1 Nagatacho Sanno Park Tower Chiyoda-ku, Tokyo 100-6171

Tel: (81) 3 5156 6770

Deutsche Bank AG London

1 Great Winchester Street London EC2N 2EQ United Kingdom Tel: (44) 20 7545 8000

Deutsche Bank Securities Inc.

60 Wall Street New York, NY 10005 United States of America Tel: (1) 212 250 2500

Global Disclaimer

The information and opinions in this report were prepared by Deutsche Bank AG or one of its affiliates (collectively "Deutsche Bank"). The information herein is believed to be reliable and has been obtained from public sources believed to be reliable. Deutsche Bank makes no representation as to the accuracy or completeness of such information.

Deutsche Bank may engage in securities transactions, on a proprietary basis or otherwise, in a manner inconsistent with the view taken in this research report. In addition, others within Deutsche Bank, including strategists and sales staff, may take a view that is inconsistent with that taken in this research report.

Opinions, estimates and projections in this report constitute the current judgement of the author as of the date of this report. They do not necessarily reflect the opinions of Deutsche Bank and are subject to change without notice. Deutsche Bank has no obligation to update, modify or amend this report or to otherwise notify a recipient thereof in the event that any opinion, forecast or estimate set forth herein. subsequently becomes inaccurate. Prices and availability of financial instruments are subject to change without notice. This report is provided for informational purposes only. It is not an offer or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Target prices are inherently imprecise and a product of the analyst judgement.

In August 2009, Deutsche Bank instituted a new policy whereby analysts may choose not to set or maintain a target price of certain issuers under coverage with a Hold rating. In particular, this will typically occur for "Hold" rated stocks having a market cap smaller than most other companies in its sector or region. We believe that such policy will allow us to make best use of our resources. Please visit our website at http://gm.db.com to determine the target price of any stock.

The financial instruments discussed in this report may not be suitable for all investors and investors must make their own informed investment decisions. Stock transactions can lead to losses as a result of price fluctuations and other factors. If a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the investment. Past performance is not necessarily indicative of future results. Deutsche Bank may with respect to securities covered by this report, sell to or buy from customers on a principal basis, and consider this report in deciding to trade on a

Unless governing law provides otherwise, all transactions should be executed through the Deutsche Bank entity in the investor's home jurisdiction. In the U.S. this report is approved and/or distributed by Deutsche Bank AG Frankfurt authorized by the BaFin. In the United Kingdom this report is approved and/or communicated by Deutsche Bank AG. Frankfurt authorized by the BaFin. In the United Kingdom this report is approved and/or communicated by Deutsche Bank AG. London, a member of the London Stock Exchange and regulated by the Financial Conduct Authority for the conduct of investment business in the UK and authorized by the BaFin. This report is distributed in Hong Kong by Deutsche Bank AG, Hong Kong Branch, in Korea by Deutsche Securities Korea Co. This report is distributed in Singapore by Deutsche Bank AG, Singapore Branch or Deutsche Securities Asia Limited, Singapore Branch (One Raffles Quay #18-00 South Tower Singapore 04583, +65 6423 8001), and recipients in Singapore of this report are to contact Deutsche Bank AG, Singapore Branch or Deutsche Securities Asia Limited, Singapore Branch and accredited investor, expert investor or institutional investor (as defined in the applicable Singapore Branch accepts legal responsibility to such person for the contents of this report. In Japan this report is approved and/or distributed by Deutsche Securities Inc. The information contained in this report does not constitute the provision of investment advice. In Australia, retail clients should obtain a copy of a Product Disclosure Statement (PDS) relating to any financial product referred to in this report and of the PDS before making any decision about whether to acquire the product. Deutsche Bank AG Johannesburg is incorporated in the Federal Republic of Germany (Branch Register Number in South Africa: 1998/003298/10). Additional information relative to se

Copyright © 2014 Deutsche Bank AG